Market Research Reports and Industry Reports

Biliary Cirrhosis - Pipeline Review, H2 2015

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Summary
 
 Global Markets Direct’s, ‘Biliary Cirrhosis - Pipeline Review, H2 2015’, provides an overview of the Biliary Cirrhosis’s therapeutic pipeline.
 
 This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Biliary Cirrhosis and special features on late-stage and discontinued projects.
 
 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
 
 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
 
 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 
 Scope
 
 - The report provides a snapshot of the global therapeutic landscape of Biliary Cirrhosis
 - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
 - The report reviews key players involved in the therapeutics development for Biliary Cirrhosis and enlists all their major and minor projects
 - The report summarizes all the dormant and discontinued pipeline projects
 - A review of the Biliary Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
 - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 - A detailed assessment of monotherapy and combination therapy pipeline projects
 - Coverage of the Biliary Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
 - Latest news and deals relating related to pipeline products
 
 Reasons to buy
 
 - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
 - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 - Develop strategic initiatives by understanding the focus areas of leading companies
 - Identify and understand important and diverse types of therapeutics under development for Biliary Cirrhosis
 - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
 - Devise corrective measures for pipeline projects by understanding Biliary Cirrhosis pipeline depth and focus of Indication therapeutics
 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents 2
 List of Tables 5
 List of Figures 5
 Introduction 6
 Global Markets Direct Report Coverage 6
 Biliary Cirrhosis Overview 7
 Therapeutics Development 8
 Pipeline Products for Biliary Cirrhosis - Overview 8
 Pipeline Products for Biliary Cirrhosis - Comparative Analysis 9
 Biliary Cirrhosis - Therapeutics under Development by Companies 10
 Biliary Cirrhosis - Pipeline Products Glance 11
 Late Stage Products 11
 Clinical Stage Products 12
 Early Stage Products 13
 Biliary Cirrhosis - Products under Development by Companies 14
 Biliary Cirrhosis - Companies Involved in Therapeutics Development 15
 AlbireoPharma 15
 CymaBay Therapeutics, Inc. 16
 Dr. Falk Pharma GmbH 17
 Enanta Pharmaceuticals, Inc. 18
 GlaxoSmithKline Plc 19
 Intercept Pharmaceuticals, Inc. 20
 Johnson & Johnson 21
 MediGene AG 22
 NGM Biopharmaceuticals, Inc. 23
 Shire Plc 24
 Virobay Inc. 25
 Biliary Cirrhosis - Therapeutics Assessment 26
 Assessment by Monotherapy Products 26
 Assessment by Target 27
 Assessment by Mechanism of Action 29
 Assessment by Route of Administration 31
 Assessment by Molecule Type 33
 Drug Profiles 35
 A-4250 - Drug Profile 35
 Product Description 35
 Mechanism of Action 35
 R&D Progress 35
 budesonide - Drug Profile 36
 Product Description 36
 Mechanism of Action 36
 R&D Progress 36
 FFP-104 - Drug Profile 39
 Product Description 39
 Mechanism of Action 39
 R&D Progress 39
 GSK-2330672 - Drug Profile 40
 Product Description 40
 Mechanism of Action 40
 R&D Progress 40
 MBX-8025 - Drug Profile 41
 Product Description 41
 Mechanism of Action 41
 R&D Progress 41
 NGM-282 - Drug Profile 43
 Product Description 43
 Mechanism of Action 43
 R&D Progress 43
 obeticholic acid - Drug Profile 44
 Product Description 44
 Mechanism of Action 44
 R&D Progress 44
 RhuDex - Drug Profile 47
 Product Description 47
 Mechanism of Action 47
 R&D Progress 47
 SHP-625 - Drug Profile 49
 Product Description 49
 Mechanism of Action 49
 R&D Progress 49
 Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - Drug Profile 50
 Product Description 50
 Mechanism of Action 50
 R&D Progress 50
 ustekinumab - Drug Profile 51
 Product Description 51
 Mechanism of Action 51
 R&D Progress 51
 VBY-825 - Drug Profile 54
 Product Description 54
 Mechanism of Action 54
 R&D Progress 54
 Biliary Cirrhosis - Recent Pipeline Updates 55
 Biliary Cirrhosis - Dormant Projects 69
 Biliary Cirrhosis - Product Development Milestones 70
 Featured News & Press Releases 70
 Jun 29, 2015: Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis 70
 Apr 13, 2015: Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 70
 Mar 24, 2015: NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine 72
 Feb 05, 2015: Initiation of a Phase II Trial for A4250, the Company’s Lead Compound for Cholestatic Liver Diseases and NASH 73
 Nov 08, 2014: Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis 74
 May 28, 2014: Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis 75
 Apr 12, 2014: Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session 75
 Apr 11, 2014: Intercept Announces Preclinical Data Demonstrating OCAs Potential Role in Preventing Complications of Cirrhosis 77
 Apr 04, 2014: Data From Intercepts Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014 77
 Mar 16, 2014: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results 79
 Appendix 81
 Methodology 81
 Coverage 81
 Secondary Research 81
 Primary Research 81
 Expert Panel Validation 81
 Contact Us 81
 Disclaimer 82


List Of Tables

 Number of Products under Development for Biliary Cirrhosis, H2 2015 8
 Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015 9
 Number of Products under Development by Companies, H2 2015 10
 Comparative Analysis by Late Stage Development, H2 2015 11
 Comparative Analysis by Clinical Stage Development, H2 2015 12
 Comparative Analysis by Early Stage Development, H2 2015 13
 Products under Development by Companies, H2 2015 14
 Biliary Cirrhosis - Pipeline by AlbireoPharma, H2 2015 15
 Biliary Cirrhosis - Pipeline by CymaBay Therapeutics, Inc., H2 2015 16
 Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H2 2015 17
 Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2015 18
 Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H2 2015 19
 Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015 20
 Biliary Cirrhosis - Pipeline by Johnson & Johnson, H2 2015 21
 Biliary Cirrhosis - Pipeline by MediGene AG, H2 2015 22
 Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015 23
 Biliary Cirrhosis - Pipeline by Shire Plc, H2 2015 24
 Biliary Cirrhosis - Pipeline by Virobay Inc., H2 2015 25
 Assessment by Monotherapy Products, H2 2015 26
 Number of Products by Stage and Target, H2 2015 28
 Number of Products by Stage and Mechanism of Action, H2 2015 30
 Number of Products by Stage and Route of Administration, H2 2015 32
 Number of Products by Stage and Molecule Type, H2 2015 34
 Biliary Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2015 55
 Biliary Cirrhosis - Dormant Projects, H2 2015 69


List Of Figures

 Number of Products under Development for Biliary Cirrhosis, H2 2015 8
 Number of Products under Development for Biliary Cirrhosis - Comparative Analysis, H2 2015 9
 Number of Products under Development by Companies, H2 2015 10
 Comparative Analysis by Late Stage Development, H2 2015 11
 Comparative Analysis by Clinical Stage Development, H2 2015 12
 Assessment by Monotherapy Products, H2 2015 26
 Number of Products by Top 10 Targets, H2 2015 27
 Number of Products by Stage and Top 10 Targets, H2 2015 27
 Number of Products by Top 10 Mechanism of Actions, H2 2015 29
 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 29
 Number of Products by Top 10 Routes of Administration, H2 2015 31
 Number of Products by Stage and Top 10 Routes of Administration, H2 2015 31
 Number of Products by Top 10 Molecule Types, H2 2015 33
 Number of Products by Stage and Top 10 Molecule Types, H2 2015 33


Japan Single-lumen Biliary Catheters Market Report 2016

Notes:Sales, means the sales volume of Single-lumen Biliary CathetersRevenue, means the sales value of Single-lumen Biliary CathetersThis report studies sales (consumption) of Single-lumen Biliary Catheters in Japan market, focuses on

USD 3400View Report

Primary Biliary Cirrhosis - Epidemiology Forecast To 2023

DelveInsight Primary Biliary Cirrhosis - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Primary Biliary Cirrhosis in seven major markets (US, France, Germany, Italy, Spain, UK

USD 2750View Report

Global Single-lumen Biliary Catheters Sales Market Report 2016

Notes:Sales, means the sales volume of Single-lumen Biliary CathetersRevenue, means the sales value of Single-lumen Biliary CathetersThis report studies sales (consumption) of Single-lumen Biliary Catheters in Global market, especially in

USD 4000View Report

Liver Cirrhosis - Epidemiology Forecast To 2023

DelveInsight Liver Cirrhosis - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Liver Cirrhosis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).

USD 2750View Report

Primary Biliary Cirrhosis - Epidemiology Forecast To 2023

DelveInsight Primary Biliary Cirrhosis - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Primary Biliary Cirrhosis in seven major markets (US, France, Germany, Italy, Spain, UK

USD 2750View Report

Liver Cirrhosis - Pipeline Review, H2 2016

Liver Cirrhosis - Pipeline Review, H2 2016Global Markets Directs, Liver Cirrhosis - Pipeline Review, H2 2016, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information

USD 2000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprise Wide Licence    $ 6000
$ 2000

Reports Details

Published Date : Jul 2015
No. of Pages :82
Country :Global
Category :Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment